KIJI THERAPEUTICS

a new era for IPSC-MSC

Welcome to Kiji Therapeutics, an international biotech company based in France and Spain dedicated to delivering a new era of IPSC-MSC engineered cell therapy for inflammatory diseases.

about us

With a scientific foundation built upon collaboration with three renowned institutions – CIBER, Fundación Jiménez Díaz, and CIEMAT – KIJI Tx is delivering a new era of IPSC-MSC engineered cell therapy for the treatment of broad range of inflammatory diseases. These professionalized, engineered MSCs have strong preclinical data and the potential to finally fulfil the long-standing promise of MSCs. Our international team of experienced professionals is committed to bringing these innovative therapies to patients in need.

leadership

Miguel Forte

Tony Ting

Michel Andraud

María Fernández

Juan A. Bueren

Rosa María Yáñez

María Fernández

Begoña Díez

Marina Garin

Mercedes López

Juan A. Bueren, PhD (Chair)

Massimo Dominici, MD PhD

Felipe Prósper, MD PhD

Jean-Frederic Colombel, MD

Mahendra Rao, PhD

Richard Maziarz, MD

Stefanos Theoharis, PhD

Our COLLABORATORS

our investors

science

FIRST PRODUCT KJ01

Why do we need a paradigm for MSC :

We are developing gene engineered iPSC-MSCs with a superior demonstrated efficacy and improved manufacturing, consistency, and flexibility.

Our first products are IPSC-MSCS transduced with IL10 and CXCR4. Strong preclinical data show an improved efficacy through synergistic immunomodulation (IL10) and homing (CXCR4).

In addition, IPSC source offers the consistency needed to guarantee a quality manufacturing of the cells.

PIPELINE / PLATFORM

media

LATEST NEWS

February 12, 2024

Kiji – iPSC/MSC engineered cell therapy for inflammatory disease

December 14, 2023

Our CEO, Miguel Forte, spoke about Kiji Therapeutics’ projects at the Alliance for Regenerative Medicine Studios.

October 11, 2023

Miguel Forte, CEO of Kiji Therapeutics, presents the company at the Cell & Gene Meeting on the Mesa 2023

LATEST MATERIAL

November 2, 2023

Improved efficacy of mesenchymal stromal cells stably expressing CXCR4 and IL-10 in a xenogeneic graft versus host disease mouse model

LATEST EVENT

January 15, 2024

Kiji Therapeutics will be present at Advanced Therapies Week in Miami, January 16-19, 2024.

JOIN US

Thank you for your interest in joining our team. While there are no current open positions, we are always on the lookout for talented individuals to join us in the future. Please feel free to submit your resume and cover letter to so that we may keep you in mind for any upcoming opportunities.